PADKJAER; Soeren

Patent Applications and Registrations

Patent applications and USPTO patent grants for PADKJAER; Soeren.The latest application filed is for "methods of treating autoimmune disease or chronic inflammation with antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)".

Company Profile

0.9.13

PADKJAER; Soeren - Vaeloese DK
Padkjaer; Soeren - Vaerloese DK

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Methods Of Treating Autoimmune Disease Or Chronic Inflammation With Antibodies That Bind And Block Triggering Receptor Expressed On Myeloid Cells-1 (trem-1) App 20210253697 - STENNICKE; Vibeke Westphal ; et al.	2021-08-19
Methods of treating autoimmune disease or chronic inflammation with antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) Grant 10,906,975 - Stennicke , et al. February 2, 2	2021-02-02
Antibodies That Bind And Block Triggering Receptor Expressed On Myeloid Cells-1 (trem-1) App 20190194321 - STENNICKE; Vibeke Westphal ; et al.	2019-06-27
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) Grant 10,189,904 - Stennicke , et al. Ja	2019-01-29
Antibodies That Bind And Block Triggering Receptor Expressed On Myeloid Cells-1 (trem-1) App 20180105590 - STENNICKE; Vibeke Westphal ; et al.	2018-04-19
Antibodies that bind urokinase plasminogen activator Grant 9,908,944 - Padkjaer , et al. March 6, 2	2018-03-06
Antagonistic DR3 Ligands App 20170305994 - Andersen; Mette Dahl ; et al.	2017-10-26
Antagonistic DR3 ligands Grant 9,737,612 - Andersen , et al. August 22, 2	2017-08-22
Antagonistic DR3 ligands Grant 9,713,644 - Andersen , et al. July 25, 2	2017-07-25
Antibodies That Bind And Block Triggering Receptor Expressed On Myeloid Cells-1 (trem-1) App 20170190775 - STENNICKE; Vibeke Westphal ; et al.	2017-07-06
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) Grant 9,550,830 - Stennicke , et al. January 24, 2	2017-01-24
Anitbodies That Bind Urokinase Plasminogen Activator App 20160159924 - PADKJAER; Soeren ; et al.	2016-06-09
Antibodies that Bind and Block Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) App 20150274825 - Stennicke; Vibeke Westphal ; et al.	2015-10-01
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) Grant 9,000,127 - Stennicke , et al. April 7, 2	2015-04-07
Antagonistic Dr3 Ligands App 20140294853 - Andersen; Mette Dahl ; et al.	2014-10-02
Antagonistic DR3 ligands Grant 8,765,130 - Andersen , et al. July 1, 2	2014-07-01
Antagonistic Dr3 Ligands App 20130336984 - Andersen; Mette Dahl ; et al.	2013-12-19
Antagonistic Dr3 Ligands App 20130330360 - Andersen; Mette Dahl ; et al.	2013-12-12
Antibodies That Bind And Block Triggering Receptor Expressed On Myeloid Cells-1 (trem-1) App 20130309239 - Stennicke; Vibeke Westphal ; et al.	2013-11-21
Antibodies That Bind And Block Triggering Receptor Expressed On Myeloid Cells-1 (trem-1) App 20130211050 - Stennicke; Vibeke Westphal ; et al.	2013-08-15

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.